KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Acquisitions & Divestments (2018 - 2025)

Arbutus Biopharma's Change in Acquisitions & Divestments history spans 9 years, with the latest figure at $41.3 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments rose 45.61% year-over-year to $41.3 million; the TTM value through Sep 2025 reached $188.1 million, up 22.01%, while the annual FY2024 figure was $164.6 million, 24.47% up from the prior year.
  • Change in Acquisitions & Divestments for Q3 2025 was $41.3 million at Arbutus Biopharma, down from $44.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $56.7 million in Q4 2024 and bottomed at $2.0 million in Q1 2022.
  • The 5-year median for Change in Acquisitions & Divestments is $28.4 million (2024), against an average of $29.2 million.
  • The largest annual shift saw Change in Acquisitions & Divestments crashed 90.17% in 2022 before it soared 1750.0% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $20.0 million in 2021, then grew by 30.0% to $26.0 million in 2022, then surged by 77.86% to $46.2 million in 2023, then increased by 22.58% to $56.7 million in 2024, then fell by 27.18% to $41.3 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Change in Acquisitions & Divestments are $41.3 million (Q3 2025), $44.1 million (Q2 2025), and $46.1 million (Q1 2025).